In the current study we not only provide the first clinical evidence that RECQL loss may be an early event during breast cancer pathogenesis, but also show that in established invasive breast cancers, RECQL deficiency is associated with immune cell infiltration, aggressive pathology, and poor prognosis. This evidence concerns the gene RECQL and breast carcinoma.